Patents Assigned to Athena Neurosciences
  • Compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6559127
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: May 6, 2003
    Assignees: Athena Neurosciences, Inc., American Home Products Corp.
    Inventors: Michael S. Dappen, Darren B. Dressen, Francine S. Grant, Michael A. Pleiss, Cynthia Y. Robinson, Dimitrios Sarantakis, Eugene D. Thorsett
  • Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6544978
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: April 8, 2003
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: Jing Wu, Jay S. Tung, Eugene D. Thorsett, Michael A. Pleiss, Jeffrey S. Nissen, R. Jeffrey Neitz, Lee H. Latimer, Varghese John, Stephen Freedman, Thomas C. Britton, James A. Audia, Jon K. Reel, Thomas E. Mabry, Bruce A. Dressman, Cynthia L. Cwi, James J. Droste, Steven S. Henry, Stacey L. McDaniel, William Leonard Scott, Russell D. Stucky, Warren J. Porter
  • Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6541466
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: April 1, 2003
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: Jing Wu, Jay S. Tung, Eugene D. Thorsett, Michael A. Pleiss, Jeffrey S. Nissen, R. Jeffrey Neitz, Lee H. Latimer, Varghese John, Stephen Freedman, Thomas C. Britton, James A. Audia, Jon K. Reel, Thomas E. Mabry, Bruce A. Dressman, Cynthia L. Cwi, James J. Droste, Steven S. Henry, Stacey L. McDaniel, William Leonard Scott, Russell D. Stucky, Warren J. Porter
  • Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6506782
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: January 14, 2003
    Assignees: Athena Neurosciences, Inc., Eli Lilly Company
    Inventors: Eugene D. Thorsett, Warren J. Porter, Jeffrey S. Nissen, Lee H. Latimer, James E. Audia, James Droste
  • N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6495693
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: December 17, 2002
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: James E. Audia, Beverly K. Folmer, Varghese John, Lee H. Latimer, Jeffrey S. Nissen, Warren J. Porter, Eugene D. Thorsett, Jing Wu
  • Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6492421
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: December 10, 2002
    Assignees: Athena Neurosciences, Inc., American Home Products Corp.
    Inventors: Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Louis John Lombardo, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Michael S. Dappen, Reinhardt Bernhard Baudy, Susan Ashwell
  • Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6423688
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: July 23, 2002
    Assignees: Athena Neurosciences, Inc., American Home Products Corp.
    Inventors: Eugene D. Thorsett, Christopher M. Semko, Michael A. Pleiss, Louis John Lombardo, Francine S. Grant, Darren B. Dressen, Michael S. Dappen
  • N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6399628
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: June 4, 2002
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: James E. Audia, Beverly K. Folmer, Varghese John, Lee H. Latimer, Jeffrey S. Nissen, Jon K. Reel, Eugene D. Thorsett, Celia A. Whitesitt
  • Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6362341
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: March 26, 2002
    Assignees: Athena Neurosciences, Inc., American Home Products
    Inventors: Eugene D. Thorsett, Christopher M. Semko, Michael A. Pleiss, Louis John Lombardo, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Michael S. Dappen
  • N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6333351
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: December 25, 2001
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: Jing Wu, Eugene D. Thorsett, Jeffrey S. Nissen, Thomas E. Mabry, Lee H. Latimer, Varghese John, Lawrence Y. Fang, James E. Audia
  • N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6313152
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: November 6, 2001
    Assignees: Athena Neurosciences, Inc., Eli Lilly and Company
    Inventors: Jing Wu, Eugene D. Thorsett, Jeffrey S. Nissen, Thomas E. Mabry, Lee H. Latimer, Varghese John, Lawrence Y. Fang, James E. Audia
  • 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6291453
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: September 18, 2001
    Assignees: Athena Neurosciences, Inc., American Home Products Corp.
    Inventors: Susan Ashwell, Francine S. Grant, Andrei W. Konradi, Anthony Kreft, Louis John Lombardo, Michael A. Pleiss, Dimitrios Sarantakis, Christopher M. Semko, Eugene D. Thorsett
  • N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
    Patent number: 6117901
    Abstract: Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: September 12, 2000
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: Jing Wu, Eugene D. Thorsett, Jeffrey S. Nissen, Thomas E. Mabry, Lee H. Latimer, Varghese John, Lawrence Y. Fang, James E. Audia
  • N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6096782
    Abstract: Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: August 1, 2000
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: James E. Audia, Beverly K. Folmer, Varghese John, Lee H. Latimer, Jeffrey S. Nissen, Warren J. Porter, Eugene D. Thorsett, Jing Wu
  • N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 5965614
    Abstract: Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: October 12, 1999
    Assignee: Athena Neurosciences, Inc.
    Inventors: James E. Audia, Beverly K. Folmer, Varghese John, Lee H. Latimer, Jeffrey S. Nissen, Jon K. Reel, Eugene D. Thorsett, Celia A. Whitesitt
  • Inhibition of phospholipase A.sub.2 to reduce neuronal cell death
    Patent number: 5866318
    Abstract: The invention is drawn to a method for identifying agents that inhibit neural degeneration by administering to cell populations consisting essentially of neurons or cells from neuronal cell lines, where these cells are exposed to an apoptotic stimulus other than APP gene products, an agent, where it is determined whether the agent inhibits neural degeneration.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 2, 1999
    Assignee: Athena Neurosciences, Inc.
    Inventors: Russell E. Rydel, Michael S. Dappen
  • Cathepsin and methods and compositions for inhibition thereof
    Patent number: 5858982
    Abstract: Methods for inhibiting the secretion of .beta.-amyloid peptide (.beta.AP) from cells comprise administering to the cells certain compounds which inhibit the activity of an approximately 31 kD protease involved in .beta.AP secretion. The 31 kD protease has been designated Cathepsin Y. Screening methods for .beta.AP inhibitors rely on determining the activity of test compounds in the presence of Cathepsin Y and a suitable peptide substrate. This invention is also directed to a nucleic acid sequence that encodes Cathepsin Y and the expression and isolation of Cathepsin Y.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: January 12, 1999
    Assignee: Athena Neurosciences, Inc.
    Inventors: Jay S. Tung, Sukanto Sinha, Christopher M. F. Semko
  • Transgenic rodents harboring APP allele having swedish mutation
    Patent number: 5850003
    Abstract: The invention provides transgenic non-human animals, such as transgenic rodents and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: December 15, 1998
    Assignee: Athena Neurosciences
    Inventors: Lisa C. McLonlogue, Jun Zhao
  • Cathepsin and methods and compositions for inhibition thereof
    Patent number: 5849711
    Abstract: Methods for inhibiting the secretion of .beta.-amyloid peptide (.beta.AP) from cells comprise administering to the cells certain compounds which inhibit the activity of an approximately 31 kD protease involved in .beta.AP secretion. The 31 kD protease has been designated Cathepsin Y. Screening methods for .beta.AP inhibitors rely on determining the activity of test compounds in the presence of Cathepsin Y and a suitable peptide substrate. This invention is also directed to a nucleic acid sequence that encodes Cathepsin Y and the expression and isolation of Cathepsin Y.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 15, 1998
    Assignee: Athena Neurosciences, Inc.
    Inventors: Jay S. Tung, Sukanto Sinha, Lisa McConlogue, Christopher M. F. Semko
  • Humanized antibodies against leukocyte adhesion molecule VLA-4
    Patent number: 5840299
    Abstract: The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.
    Type: Grant
    Filed: November 21, 1995
    Date of Patent: November 24, 1998
    Assignee: Athena Neurosciences, Inc.
    Inventors: Mary M. Bendig, Olivier J. Leger, Jose Saldanha, S. Tarran Jones, Ted A. Yednock